Abe Yuko, Suga Yasuhiko, Fukushima Kiyoharu, Ohata Hayase, Niitsu Takayuki, Nabeshima Hiroshi, Nagahama Yasuharu, Kida Hiroshi, Kumanogoh Atsushi
Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Laboratory of Host Defense, World Premier Institute Immunology Frontier Research Center (WPI-IFReC), Osaka University, Osaka 565-0871, Japan.
Int J Mol Sci. 2021 Dec 22;23(1):83. doi: 10.3390/ijms23010083.
Asthma is a disease that consists of three main components: airway inflammation, airway hyperresponsiveness, and airway remodeling. Persistent airway inflammation leads to the destruction and degeneration of normal airway tissues, resulting in thickening of the airway wall, decreased reversibility, and increased airway hyperresponsiveness. The progression of irreversible airway narrowing and the associated increase in airway hyperresponsiveness are major factors in severe asthma. This has led to the identification of effective pharmacological targets and the recognition of several biomarkers that enable a more personalized approach to asthma. However, the efficacies of current antibody therapeutics and biomarkers are still unsatisfactory in clinical practice. The establishment of an ideal phenotype classification that will predict the response of antibody treatment is urgently needed. Here, we review recent advancements in antibody therapeutics and novel findings related to the disease process for severe asthma.
气道炎症、气道高反应性和气道重塑。持续性气道炎症会导致正常气道组织的破坏和退化，导致气道壁增厚、可逆性降低以及气道高反应性增加。不可逆性气道狭窄的进展以及相关的气道高反应性增加是重度哮喘的主要因素。这导致了有效药理靶点的确定以及几种生物标志物的识别，从而能够对哮喘采取更个性化的治疗方法。然而，目前抗体疗法和生物标志物的疗效在临床实践中仍不尽人意。迫切需要建立一种理想的表型分类来预测抗体治疗的反应。在此，我们综述了抗体疗法的最新进展以及与重度哮喘疾病过程相关的新发现。
